Researcher Awarded Patent For System To Fight Multiple Diseases

St. Louis, April 13, 1999 -- After waiting for nearly 18 years, Roy Curtiss III, Ph.D., George William and Irene Koechig Freiberg Professor of Biology at Washington University in St. Louis, was granted a United States patent for his genetically engineered bacterial antigen delivery system March 30, 1999.

The patent, "Recombinant Avirulent Bacterial Antigen Delivery System," is number 5, 888, 799. It was originally filed on October 22, 1981. Washington University and the University of Alabama, Birmingham (UAB) will share patent income equally from any vaccine marketed to combat any bacterial, viral, fungal or parasitic disease using Curtiss' concept.

Curtiss developed the system while on the faculty of UAB in the late 1970s and early 1980s and at Washington University since 1983. The patent covers composition, manufacture and use of live attenuated, or weakened, derivatives of disease-causing bacteria genetically engineered to express foreign antigens, or proteins, in a vaccine; the vaccine then homes in on lymph tissue in an individual to induce immune responses against the foreign antigens.

Curtiss conceived the initial ideas for the patent in the late 1970s and early 1980s when he was using gene cloning to express protein antigens from streptococcal bacteria in E. coli. One purpose of these studies was to develop a recombinant vaccine that would induce anti-streptococcal immunity in an individual after taking an oral vaccine.

In 1981, when Curtiss filed the patent application, introducing genes from one pathogen into another was not possible because such gene cloning was prohibited by the National Institutes of Health (NIH) Guidelines for Recombinant DNA Research. Curtiss helped draft the guidelines in the 1970s as an original member of the NIH Recombinant DNA Advisory Committee. Although international patents on this technology first were granted in 1989, the U.S. Patent and Trademark Office had ru

Contact: Tony Fitzpatrick
Washington University in St. Louis

Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:

(Date:4/22/2020)... ... ... RCH Solutions (RCH ), a global provider of Bio-IT computing expertise for ... as Director of Sales and Business Development. Based out of RCH’s location in Boston, ... across the Northeast. , “We continue to see increased demand for specialized scientific computing ...
(Date:4/18/2020)... , ... April 16, 2020 , ... SIRION Biotech ... cell therapy, today announced it will present a company update on its work expediting ... Summit taking place on April 22 and 23. Dieter Lingelbach, the Company’s Chief ...
(Date:4/15/2020)... , ... April 15, 2020 , ... NDA Partners Chairman ... FAAPM, FHPS , former Senior Science Policy Advisor with the Center for Drug Evaluation ... Center for Devices and Radiological Health, has joined the firm as an Expert Consultant. ...
Breaking Biology News(10 mins):
(Date:4/18/2020)... ... April 17, 2020 , ... ... Small Business Innovation Research (SBIR) program to support the expansion of its digital ... the NSF, which conducts a rigorous merit-based review process, adds to NeuroFlow’s ...
(Date:4/1/2020)... ... March 30, 2020 , ... Kinetic Vet, an ... an EPA-approved spray-on antimicrobial solution. As a first-of-its-kind technology within the animal health ... activity against microorganisms for up to 90 days. , In addition to reducing ...
(Date:4/1/2020)... CITY, and LA JOLLA, Calif. (PRWEB) , ... March 31, 2020 ... ... tools, and La Jolla Institute for Immunology (LJI), announced today that they will use ... allowing CoVIC to move therapeutic candidates to the clinic as early as this summer. ...
(Date:3/27/2020)... ... , ... iFirst Medical Technologies, Inc., a leader in handheld diagnostic devices, announced ... poses a grave danger to public health here in the U.S. and around the ... Broad-based testing and on-the-spot results promise to slow the spread and save human lives." ...
Breaking Biology Technology:
Cached News: